Key result
Individualized UFH titration coincides with complete LV thrombus resolution and LVEF recovery during VA-ECMO.
Why the study?
LV thrombosis is uncommon during VA-ECMO in children, and pediatric evidence is sparse for management when intracranial hemorrhage limits anticoagulation.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Demonstrates that surgical left atrial decompression during pediatric VA-ECMO for fulminant myocarditis does not prevent LV stasis and thrombosis when anticoagulation is interrupted for intracranial hemorrhage, highlighting an imaging-guided, individualized UFH titration strategy when thrombolysis and thrombectomy are contraindicated.
Background Left ventricular (LV) thrombosis is uncommon during venoarterial extracorporeal membrane oxygenation (VA-ECMO) in children. Management is especially difficult when intracranial hemorrhage limits anticoagulation, and pediatric evidence is sparse. Case presentation A 9-year-old boy (25 kg) with fulminant myocarditis and cardiogenic shock underwent VA-ECMO with surgical LV decompression. Unfractionated heparin (UFH, 10 U/kg/h) was initially stopped for pleural-drain bleeding, resumed at low dose, and stopped again after parafalcine subarachnoid and subdural hemorrhage was identified on Day 4. After stable neuroimaging and multidisciplinary reassessment, UFH was cautiously resumed. An irregular LV apical intracavitary mass, clinically interpreted as an LV thrombus (22.3 mm × 8.5 mm), appeared on Day 7 and enlarged on Day 8. On Day 9, UFH was adjusted from 22.5 to 20 and then to 17.5 U/kg/h while maintaining an individualized activated clotting time target because of recent hemorrhage and then increased to 25 U/kg/h by Day 13 without a loading bolus. The previously described intracavitary masses were no longer visualized during continued UFH and ventricular recovery, although the contributions of these factors could not be separated. Serial echocardiography found no definite intracardiac mass on Days 16 and 17; no residual intracardiac mass was visualized before Day 18 decannulation; the left ventricular ejection fraction (LVEF) was 43%, 46%, 50%, and 52% on Days 14, 16, 17, and 18, respectively. No clinically recognized systemic arterial embolic event was documented during ECMO. A later right internal jugular vein thrombosis was managed as a separate post-ECMO venous thrombotic complication. Nadroparin was introduced after decannulation for post-ECMO venous thromboembolism risk. At 1 month, the LVEF was 47%; a follow-up revealed independent walking, school return, and no recurrent convulsions. Conclusion Left atrial decompression does not guarantee effective LV emptying or eliminate intracavitary stasis during VA-ECMO for fulminant myocarditis, particularly when anticoagulation is constrained by hemorrhage. Serial echocardiography and multidisciplinary, patient-specific reassessment supported management of the competing thrombotic and bleeding risks; non-visualization of the previously described intracardiac masses coincided with continued UFH and ventricular recovery, but no causal treatment effect can be assigned.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a case report in Fulminant myocarditis complicated by cardiogenic shock, VA-ECMO-associated left ventricular thrombosis, and intracranial hemorrhage (n=1). Individualized unfractionated heparin (UFH) anticoagulation during VA-ECMO with surgical left atrial decompression was evaluated on Resolution of left ventricular intracavitary thrombus and survival to ECMO decannulation without systemic arterial embolization. Individualized UFH titration (10-25 U/kg/h) and ventricular recovery coincided with complete resolution of an LV thrombus by Day 16 and LVEF recovery to 52% by Day 18 decannulation.
Synapse has enriched 10 related papers. Consider them for comparative context: